RBC Capital reiterated coverage on Avalo Therapeutics with a new price target

3/3/22 8:10:44 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

RBC Capital reiterated coverage of Avalo Therapeutics with a rating of Outperform and set a new price target of $4.00 from $5.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$AVTX

Date	Price Target	Rating	Analyst
6/2/2025	$15.00	Buy	H.C. Wainwright
3/25/2025	$36.00	Buy	Stifel
3/25/2025	$23.00	Buy	Jefferies
2/28/2025	$48.00	Overweight	Piper Sandler
2/21/2025	$18.00	Outperform	Wedbush
12/19/2024	$40.00	Buy	BTIG Research
10/24/2024		Neutral	H.C. Wainwright
4/16/2024	$35.00	Perform → Outperform	Oppenheimer